We elected for the purposes of this study to define the AD CSF profile according to the BIOMARKAPD/ABSI criteria, which require all three major biomarker groups (amyloid, tau, and neurodegeneration) to be abnormal. This evidence concerns the gene MAPT and Alzheimer disease.